He Chen

Dr. He Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in Frontiers in Physiology
Verified
Journal Article
Open access
YCYinhe Cai
Yinhe Cai
JWJunmao Wen
Junmao Wen
SMSiwen Ma
Siwen Ma
ZMZhexing Mai
Zhexing Mai
QZQunzhang Zhan
Qunzhang Zhan
CLChuanjin Luo
Chuanjin Luo
Macrophage polarization plays a vital impact in triggering atherosclerosis (AS) progression and regression. Huang-Lian-Jie-Du Decoction (HLJDD), a famous traditional Chinese decoction, displays notable anti-inflammatory and lipid-lowering effects in different animal models. However, its effects and mechanisms on AS have not been clearly defined. We determined whether HLJDD attenuated atherosclerosis and plaques vulnerability by regulating macrophage polarization in ApoE−/− mice induced by high-fat diet (HFD). Furthermore, we investigated the effects of HLJDD on macrophage polarization in oxidized low-density lipoprotein (ox-LDL) induced RAW264.7 cells. For in vivo assay, compared with the model group, HLJDD ameliorated lipid metabolism, with significantly decreased levels of serum triglyceride, total cholesterol (CHOL), and lipid density lipoprotein. HLJDD suppressed serum tumor necrosis factor α (TNF-α) and IL-1β levels with increased serum IL-10 level, and inhibited mRNA level of NLRP3 inflammasome in carotid tissues. HLJDD enhanced carotid lesion stability by decreasing macrophage infiltration together with increased expression of collagen fibers and α-SMA. Moreover, HLJDD inhibited M1 macrophage polarization, which decreased the expression and mRNA levels of M1 markers [inducible nitric oxide synthase (iNOS) and CD86]. HLJDD enhanced alternatively activated macrophage (M2) activation, which increased the expression and mRNA levels of M2 markers (Arg-1 and CD163). For in vitro assay, HLJDD inhibited foam cell formation in RAW264.7 macrophages disturbed by ox-LDL. Besides, groups with ox-LDL plus HLJDD drug had a lower expression of CD86 and mRNA levels of iNOS, CD86, and IL-1β, but higher expression of CD163 and mRNA levels of Arg-1, CD163, and IL-10 than ox-LDL group. Collectively, our results revealed that HLJDD alleviated atherosclerosis and promoted plaque stability by suppressing M1 polarization and enhancing M2 polarization.

17 July 2025 in Scientific Reports
Verified
Journal Article
Open access
HCHe Chen
He Chen
SLSixing Liu
Sixing Liu
WWWeiming Wang
Weiming Wang
HSHangyu Shi
Hangyu Shi
SGShuai Gao
Shuai Gao
ZLZhishun Liu
Zhishun Liu
Substance use disorders (SUDs) among adolescents and young adults aged 10-24 years represent a major global public health challenge, contributing to various medical conditions and significant disease burden. This study analyzed global, regional, and national estimates of the SUD burden within this demographic from 1990 to 2021. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we analyzed incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of SUDs among population aged 10-24 years. SUDs in GBD 2021 encompass alcohol and drug use disorders. We calculated age-standardized rates (per 100,000 population) for incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDR). Health inequalities were assessed using the slope index of inequality (SII) and concentration index. Risk factors were also analyzed. Statistical analyses were performed in R (v4.4.1). In 2021, the global ASIR and ASPR of SUDs among population aged 10-24 years were 614.0 (95% CI 467.6-805.0) and 1557.0 (1234.1-1944.6) per 100,000 population. Substance-specific ASPRs in 2021 included alcohol (651.9, 95% CI 439.0-941.7), cannabis (536.8, 343.5-831.8), opioid use disorders (155.0, 120.0-199.7), etc. The global ASMR and ASDR for SUDs were 1.1 (1.0 to 1.2) and 228.9 (172.4-295.3). From 1990 to 2021, ASIR (average annual percent change [AAPC] - 0.70, 95% CI - 0.71 to - 0.69), ASPR (AAPC - 0.71, - 0.72 to - 0.70), and ASDR (AAPC - 0.60, - 0.63 to - 0.56) declined globally, while ASMR increased (AAPC 0.83, 0.52-1.23). During the COVID-19 pandemic (2019-2021), ASIR and ASPR decreased, ASDR remained stable, and ASMR rose. Substantial disparities were observed across regions and countries and territories. Males, older adolescents, and populations in higher socio-demographic index (SDI) regions exhibited disproportionately higher SUD burden. SUDs impose a significant health burden on adolescents and young adults aged 10-24 years, with distinct demographic and geographic inequities. Evidence-based interventions should prioritize male populations, older age groups, and the high-SDI regions. Lower-SDI regions require enhanced monitoring to address evolving epidemiological trends. Urgent implementation of targeted prevention and treatment strategies is critical to mitigate the impact of SUDs in this vulnerable population.

18 April 2024 in Current Pain and Headache Reports
Verified
Journal Article
Open access
PDF file
HCHe Chen
He Chen
HSHangyu Shi
Hangyu Shi
SGShuai Gao
Shuai Gao
JFJiufei Fang
Jiufei Fang
JYJiamin Yi
Jiamin Yi
ZLZhishun Liu
Zhishun Liu
Purpose of Review: Knee osteoarthritis (KOA) is a degenerative joint disease which can result in chronic pain and disability. The current interventions available for KOA often fail to provide long-lasting effects, highlighting the need for new treatment options that can offer durable benefits. Previous studies have suggested the efficacy of acupuncture for knee osteoarthritis (KOA) with its durability remaining uncertain. In this review, we aimed to investigate the durability of the efficacy after completion of treatment. Recent Findings: We performed thorough searches of PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials from inception to November 4, 2023. The outcomes were assessed at all available time points after completion of treatment. Primary outcomes were changes from baseline in pain and function measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function subscales. Secondary outcomes included response rate, overall pain, the WOMAC stiffness subscale, total WOMAC index, and physical and mental health components of 12/36-item Short-Form Health Survey. A total of 10 randomized controlled trials (RCTs) involving 3221 participants were included. Pooled estimates suggested that acupuncture may offer potential improvements in function and overall pain for 4.5 months post-treatment versus sham acupuncture (SA). Acupuncture may provide durable clinically important pain relief and functional improvement up to 5 months post-treatment versus usual care, and up to 6 months post-treatment versus diclofenac. For acupuncture versus no treatment, one trial with large sample size indicated that improvements in pain and function persisted for 3 months post-treatment, while the other trial reported that significant pain reduction and functional improvement were only observed at the end of the treatment, not at 9 months post-treatment. However, acupuncture as adjunct to exercise-based physical therapy (EPT) showed no superiority to SA as an adjunct to EPT or EPT alone up to 11.25 months after completion of treatment. Summary: Acupuncture may provide pain alleviation and functional improvements in KOA patients for 3 to 6 months after completion of treatment with a good safety profile.

24 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHe Chen
He Chen
SLSixing Liu
Sixing Liu
SGShuai Gao
Shuai Gao
HSHangyu Shi
Hangyu Shi
YYYan Yan
Yan Yan
ZLZhishun Liu
Zhishun Liu
We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q2–2024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide. Among 28,953 NAE reports associated with GLP-1 RAs, 19 distinct NAE signals were identified using reporting odds ratios (RORs), including dizziness, tremor, dysgeusia, lethargy, taste disorder, presyncope, parosmia, allodynia, and hypoglycemic unconsciousness, etc. Time-to-onset analysis revealed a median latency of 32 days (IQR 7–122) for GLP-1 RA-related NAEs, with 45.28% occurring within 30 days of treatment initiation. Sensitivity analyses using proportional reporting ratios (PRRs), information components (ICs), and empirical Bayes geometric means (EBGMs) confirmed robustness of these signals. While these pharmacovigilance findings underscore the need for heightened clinical vigilance, they represent associations rather than causal relationships, constrained by inherent limitations of FAERS such as reporting bias and confounding. Future prospective studies are needed to confirm these associations and clarify underlying mechanisms.

10 June 2024 in Current Pain and Headache Reports
Verified
Journal Article
Open access
PDF file
JFJiufei Fang
Jiufei Fang
HSHangyu Shi
Hangyu Shi
WWWeiming Wang
Weiming Wang
HCHe Chen
He Chen
MYMin Yang
Min Yang
ZLZhishun Liu
Zhishun Liu
Objective: Chronic neck pain, a prevalent health concern characterized by frequent recurrence, requires exploration of treatment modalities that provide sustained relief. This systematic review and meta-analysis aimed to evaluate the durable effects of acupuncture on chronic neck pain. Methods: We conducted a literature search up to March 2024 in six databases, including PubMed, Embase, and the Cochrane Library, encompassing both English and Chinese language publications. The main focus of evaluation included pain severity, functional disability, and quality of life, assessed at least 3 months post-acupuncture treatment. The risk of bias assessment was conducted using the Cochrane Risk of Bias 2.0 tool, and meta-analyses were performed where applicable. Results: Eighteen randomized controlled trials were included in the analysis. Acupuncture as an adjunct therapy could provide sustained pain relief at three (SMD: − 0.79; 95% CI − 1.13 to − 0.46; p < 0.01) and six (MD: − 18.13; 95% CI − 30.18 to − 6.07; p < 0.01) months post-treatment. Compared to sham acupuncture, acupuncture did not show a statistically significant difference in pain alleviation (MD: − 0.12; 95% CI − 0.06 to 0.36; p = 0.63). However, it significantly improved functional outcomes as evidenced by Northwick Park Neck Pain Questionnaire scores 3 months post-treatment (MD: − 6.06; 95% CI − 8.20 to − 3.92; p < 0.01). Although nine studies reported an 8.5%–13.8% probability of adverse events, these were mild and transitory adverse events. Conclusion: Acupuncture as an adjunct therapy may provide post-treatment pain relief lasting at least 3 months for patients with chronic neck pain, although it is not superior to sham acupuncture, shows sustained efficacy in improving functional impairment for over 3 months, with a good safety profile.

1 October 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
XSXinyu Shen
Xinyu Shen
SLSixing Liu
Sixing Liu
HCHe Chen
He Chen
WWWei Wang
Wei Wang
JFJiufei Fang
Jiufei Fang
ZLZhishun Liu
Zhishun Liu
Objective: Primary dysmenorrhea (PD) is a recurrent disease. The current treatments for PD often fail to provide long-lasting effects, underscoring the necessity for new treatment options that can offer durable benefits. Previous studies have indicated that the durable effect of acupuncture for PD remains uncertain. In this review, we aimed to evaluate the durable effect after completion of treatment. Methods: Both English and Chinese literature were comprehensively retrieved from eight databases up to January 24, 2025. Two independent reviewers conducted screening and data extraction. The risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. Meta-analysis was conducted where applicable. Pooled continuous data were expressed as mean differences (MD) and the safety outcomes were expressed through odds ratio (OR). Results: Fourteen randomized controlled trials enrolled 970 patients met the inclusion and exclusion criteria. Acupuncture outperformed no intervention in reducing pain intensity measured by visual analogue scale (VAS) (MD − 47.80; 95% CI − 48.63 to − 46.97; p < 0.0001) and Short-Form McGill Pain Questionnaire (MD − 8.55; 95% CI − 11.46 to − 5.64; p < 0.0001), Cox Menstrual Symptom Scale (CMSS) duration score (MD − 18.24; 95% CI − 22.39 to − 14.09; p < 0.0001) and severity score (MD − 12.96; 95% CI − 16.41 to − 9.51; p < 0.0001) at 3 menstrual cycles post-treatment. Compared to non-steroidal anti-inflammatory drugs (NSAIDs), acupuncture showed superior pain relief measured by VAS (MD − 29.89; 95% CI − 37.63 to − 22.15; p < 0.0001), and symptom amelioration measured by CMSS (MD − 3.00; 95% CI − 5.92 to − 0.08; p = 0.0043) at 3 cycles post-treatment. Acupuncture also enhanced NSAIDs’ analgesic effect measured by VAS (MD − 19.95; 95% CI − 24.23 to − 15.66; p < 0.0001). However, acupuncture presented no superiority over sham acupuncture at 3 menstrual cycles post-treatment. Conclusion: Acupuncture might provide durable post-treatment effects to primary dysmenorrhea patients up to three menstrual cycles, which was limited by high risk of bias and low certainty evidence.